Bristol Myers Squibb's ozanimod failed to meet primary endpoint in Phase 3 trial for moderate-to-severe active Crohn's disease.
Bristol Myers Squibb's experimental drug, ozanimod (Zeposia), failed to meet its primary endpoint of clinical remission in a Phase 3 YELLOWSTONE trial for treating moderate-to-severe active Crohn's disease in adults after 12 weeks of treatment. The drug's safety profile remained consistent with previous trials. The company plans to evaluate the trial data and share results with the scientific community.
March 28, 2024
6 Articles